Milestone Pharmaceuticals (MIST) vs PDS Biotechnology (PDSB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PDS Biotechnology (PDSB) has outperformed Milestone Pharmaceuticals (MIST) over the past year, gaining 40.0% versus a loss of 64.4%. Over five years, MIST leads with a -87.9% price change compared with -88.8% for PDSB. PDS Biotechnology is the larger company by market cap ($100.0 million vs $95.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MIST | PDSB |
|---|---|---|
| Share price | $0.765 | $1.38 |
| Market cap | $95.24M | $100.01M |
| 1-day change | +7.43% | +35.29% |
| YTD return | -64.75% | +79.22% |
| 1-year return | -64.39% | +39.96% |
| 5-year return | -87.93% | -88.81% |
| EPS (TTM) | $-0.68 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.06 | $1.55 |
| 52-week low | $0.7075 | $0.195 |
| Distance from 52-week high | -75.00% | -10.97% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +666.01% | +262.32% |
| Average volume | 1.40M | 23.24M |
| Shares outstanding | 124.50M | 72.47M |
| Employees | 38 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PDSB has outperformed MIST by 104.4 percentage points over the past year.
About Milestone Pharmaceuticals
MIST stock →Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
MIST vs PDSB FAQ
Which is bigger, Milestone Pharmaceuticals or PDS Biotechnology?
PDS Biotechnology (PDSB) is larger, with a market capitalization of $100.01M compared with $95.24M for Milestone Pharmaceuticals (MIST).
Which stock has performed better over the past year, MIST or PDSB?
PDSB returned +39.96% over the past 12 months, compared with -64.39% for MIST (price return, excluding dividends). Past performance does not predict future results.
Are Milestone Pharmaceuticals and PDS Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.